Michel Bublot is a veterinarian with a PhD in Virology from University of Liège (Belgium). He has been working in R&D department in the pharmaceutical industry in France and USA for 29 years. He has been heavily involved in the research, development, licensing and/or product support of new bivalent and trivalent vector vaccines against IBD, ND, ILT, and AI, as well as in a new genetically modified serotype 1 Marek’s disease vaccine. He is the author of numerous scientific publications and inventor in several patents. He is currently pre-retired and has a consulting activity.
Related Session/Presentation:
Keynote Paper 9
Current and Future Avian Vaccine Technology: What Makes Avian Vaccine a Game Changer?
